Takeda

Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout
Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout
Fierce Pharma
Shire
FDA
Takeda
M&A
Flag link:
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
CP Wire
Takeda
Alunbrig
Xalkori
non-small cell lung cancer
Flag link:
Takeda's Alunbrig Showed Superior Intracranial Results Compared to Xalkori in Ph III Trial in Non-Small Cell Lung Cancer
Takeda
Alunbrig
Xalkori
non-small cell lung cancer
Flag link:
Seattle Genetics' Adcetris Has Potential to Change Treatment for T-Cell Lymphoma
Seattle Genetics' Adcetris Has Potential to Change Treatment for T-Cell Lymphoma
BioSpace
Seattle Genetics
Takeda
Adcetris
peripheral T-cell lymphoma
Flag link:
Disgruntled Takeda alums demand a window into $62B Shire buy
Disgruntled Takeda alums demand a window into $62B Shire buy
Fierce Pharma
Takeda
Shire
M&A
Flag link:
Seattle Genetics' and Takeda's Adcetris Meets Primary and Secondary Endpoints in Ph III Trial for T-Cell Lymphoma
Seattle Genetics' and Takeda's Adcetris Meets Primary and Secondary Endpoints in Ph III Trial for T-Cell Lymphoma
CP Wire
Seattle Genetics
Takeda
Adcetris
T-cell lymphoma
Flag link:
Seattle Genetics' and Takeda's Adcetris Meets Primary and Secondary Endpoints in Ph III Trial for T-Cell Lymphoma
Seattle Genetics
Takeda
Adcetris
T-cell lymphoma
Flag link:
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
CP Wire
Takeda
Alunbrig
non-small cell lung cancer
Flag link:
Takeda Presents Superior Results for Alunbrig in ALK+ Non-Small Cell Lung Cancer
Takeda
Alunbrig
non-small cell lung cancer
Flag link:
Takeda blesses a little biotech’s engineered toxin tech for multiple myeloma, triggering a bases loaded home run
Takeda blesses a little biotech’s engineered toxin tech for multiple myeloma, triggering a bases loaded home run
Endpoints
Molecular Templates
Takeda
Multiple Myeloma
Flag link:
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
CP Wire
Exelixis
Cabometyx
Takeda
Canada
Japan
Ipsen
renal cell carcinoma
Flag link:
Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt
Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt
Bloomberg
Takeda
Shire
M&A
Xiidra
Flag link:
Takeda shuttering Chicago complex with 1,000 staffers in lead-up to Shire merger
Takeda shuttering Chicago complex with 1,000 staffers in lead-up to Shire merger
Endpoints
Takeda
Shire
M&A
layoffs
Flag link:
Traditionalists at Takeda spark a family feud with CEO Christophe Weber over his $62B Shire takeover deal
Traditionalists at Takeda spark a family feud with CEO Christophe Weber over his $62B Shire takeover deal
Endpoints
Takeda
Pharma CEOs
Christophe Weber
Shire
M&A
Flag link:
Shire Secures FDA Approval for HAE Drug Lanadelumab
Shire Secures FDA Approval for HAE Drug Lanadelumab
BioSpace
Shire
Takeda
HAE
hereditary angiodema
Takhzyro
lanadelumab
FDA
Flag link:
Janssen, Lundbeck and Takeda Raise Issues With FDA Draft Guidance on MDD Drugs
Janssen, Lundbeck and Takeda Raise Issues With FDA Draft Guidance on MDD Drugs
RAPS.org
FDA
JNJ
Janssen
Lundbeck
Takeda
major depressive disorder
drug development
Flag link:
Shire dodges pricing questions as lanadelumab’s big day nears
Shire dodges pricing questions as lanadelumab’s big day nears
EP Vantage
Takeda
HAE
lanadelumab
FDA
Flag link:
Third Rock and Takeda Fund $140 Million Startup to Create Regenerative Therapies for Liver Diseases
Third Rock and Takeda Fund $140 Million Startup to Create Regenerative Therapies for Liver Diseases
CP Wire
Ambys Medicines
Takeda
Third Rock
Flag link:
Takeda announces new series of non-core-asset sales
Takeda announces new series of non-core-asset sales
GoinPharma
Takeda
Shire
M&A
Flag link:
Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?
Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?
Endpoints
Takeda
Shire
M&A
Flag link:

Pages